Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Apply
Combination Treatment
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step